APTAMER-TARGETED SIRNA TO PREVENT ATTENUATION OR SUPPRESSION OF A T CELL FUNCTION

• US 20100240732A1
• Filed: 04/01/2010
• Published: 09/23/2010
• Est. Priority Date: 10/01/2007
• Status: Abandoned Application

• Current Assignee: University of Miami
• Original Assignee: University of Miami
• Inventors: Gilboa, Eli
• Application Number:
  US12/752,802
• Publication Number:
  US 20100240732A1
• Time in Patent Office: Days
• US Class Current: 514/44.A
• CPC Class Codes: A61K 31/7088 Compounds having three or more nucleosides or nucleotides
• CPC Class Codes: A61K 31/7115 Nucleic acids or oligonucleotides having modified bases, i.e. other than adenine, guanine, cytosine, uracil or thymine
• CPC Class Codes: A61P 35/00 Antineoplastic agents
• CPC Class Codes: A61P 37/06 Immunosuppressants, e.g. drugs for graft rejection
• CPC Class Codes: C12N 15/1138 against receptors or cell surface proteins
• CPC Class Codes: C12N 15/115 Aptamers, i.e. nucleic acids binding a target molecule specifically and with high affinity without hybridising therewith ; Nucleic acids binding to non-nucleic acids, e.g. aptamers
• CPC Class Codes: C12N 2310/14 interfering N.A.
• CPC Class Codes: C12N 2310/16 Aptamers
• CPC Class Codes: C12N 2310/3519 Fusion with another nucleic acid
• CPC Class Codes: C12N 2320/32 Special delivery means, e.g. tissue-specific

Abstract

Compositions for countering immune attenuating/suppressive pathways comprise targeting agents or aptamer targeted RNAi-mediated gene silencing (siRNA/shRNA). These compositions have broad applicability in the treatment of many diseases.

Claims

1. A composition for modulating immune cells comprising an aptamer-interference RNA (RNAi) fusion molecule wherein said molecule is targeted to cells and cellular molecules associated with regulation of an immune response and comprises at least one aptamer specific for at least one molecule.

2. The composition of claim 1, wherein the interference RNA comprising at least one of a short interfering RNA (siRNA);

a micro, interfering RNA (miRNA);

a small, temporal RNA (stRNA);

or a short, hairpin RNA (shRNA).

3. The composition of claim 1, wherein the immune cells comprise T cells (T lymphocytes), B cells (B lymphocytes), antigen presenting cells, dendritic cells, monocytes, macrophages, myeloid suppressor cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), CTL lines, CTL clones, CTLs from tumor, inflammatory, or other infiltrates and subsets thereof.

4. The composition of claim 3, wherein the aptamer is specific for T lymphocytes and subsets thereof.

5. The composition of claim 4, wherein the aptamer is specific for CD8⁺T lymphocytes and markers thereof.

6. The composition of claim 1, wherein the aptamer is specific for T regulatory cells.

7. The composition of claim 1, wherein the aptamer is specific for molecules comprising 4-1BB (CD137), OX40, CD3, CD28, HLA-ABC, HLA-DR, T Cell receptor α

β

(TCRα

β

), T Cell receptor γ

δ

(TCRγ

δ

), T cell receptor ζ

(TCRζ

), TNF receptor, Cd11c, CD1-339, B7, mannose receptor, or DEC205, variants, mutants, ligands, alleles and fragments thereof.

8. The composition of claim 1, wherein the interference RNA (RNAi) is specific for polynucleotides comprising TGFβ

receptor, polynucleotides associated with TGFβ

signaling, purinergic receptors, CTLA-4, PTEN, Csk, Cb1-b, cytokines, SOCS1, GILT, GILZ, A20 or Bax/Bak.

9. The composition of claim 8 wherein the interference RNA (RNAi) is specific for polynucleotides associated with TGFβ

signaling.

10. The composition of claim 1 wherein the RNAi targets TGFβ

in activated T lymphocytes.

11. The composition of claim 1, wherein the aptamer-RNA interference fusion molecule comprises at least one oligonucleotide as set froth in SEQ ID NOS:

1-6.

12. A method of modulating an immune response in patient comprising:

constructing an aptamer and/or targeting agent and interference RNA fusion molecule wherein the aptamer and/or targeting agent is specific for an immune effector cell and the interference RNA is specific for a molecule associated with attenuation or suppression of the immune effector cell;

administering the fusion molecule in a therapeutically effective amount to the patient; and

,

modulating the immune response.

13. The method of claim 12, wherein the aptamer and or targeting agent are specific for an activated CD8⁺T lymphocyte or CD8⁺T lymphocyte molecules thereof, and the interference RNA is specific for TGFβ

, TGFβ

RII, variants, mutants and fragments thereof.

14. The method of claim 12, wherein an aptamer-interference RNA comprises at least one of an oligonucleotide as set forth in SEQ ID NOS:

1-6.

15. The method of claim 12, wherein the aptamer-interference RNA fusion molecule comprising:

at least one aptamer specific for a desired cell marker for targeting the fusion molecule, and at least one interference RNA molecule specific for a desired polynucleotide.

16. The method of claim 12, wherein the aptamer-interference RNA fusion molecule comprises a linker molecule.

17. The method of claim 12, wherein the polynucleotide encoding the aptamer-interference RNA fusion molecule comprises one or more nucleotide substitutions.

18. The method of claim 17, wherein the nucleotide substitutions comprise at least one or combinations thereof, of adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N⁶-methyladenine, 7-deazaxanthine, 7-deazaguanine, N⁴,N⁴-ethanocytosin, N⁶,N⁶-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C³-C⁶)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, inosine, non-naturally occurring nucleobases, locked nucleic acids (LNA), peptide nucleic acids (PNA), variants, mutants and analogs thereof.

19. The method of claim 12, wherein the linker molecule comprises nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker joining the one or more aptamers to on or more interference RNA molecules.

20. The method of claim 19, wherein the one or more linker molecules comprising about 2 nucleotides length up to about 50 nucleotides in length.

21. The method of claim 19, wherein the non-nucleotide linker comprising abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or polymeric compounds having 1 or more monomeric units.

22. An aptamer-interference RNA molecule comprising at least one aptamer specific for a marker of a target cell and at least one interference RNA molecule specific for a desired polynucleotide of the target cell.

23. The aptamer-interference RNA molecule of claim 22, wherein the at least one aptamer is linked to the at least interference RNA by at least one linker molecule.

24. The aptamer-interference RNA molecule of claim 23, wherein the linker molecule comprises wherein the linker molecule comprises nucleotide, non-nucleotide, or mixed nucleotide/non-nucleotide linker joining the one or more aptamers to on or more interference RNA molecules.

25. The aptamer-interference RNA molecule of claim 23, wherein the one or more linker molecules comprising about 2 nucleotides length up to about 50 nucleotides in length.

26. The aptamer-interference RNA molecule of claim 23, wherein the non-nucleotide linker comprises abasic nucleotide, polyether, polyamine, polyamide, peptide, carbohydrate, lipid, polyhydrocarbon, or polymeric compounds having 1 or more monomeric units.

27. The aptamer-interference RNA molecule of claim 23, wherein the polynucleotide encoding the aptamer-interference RNA fusion molecule comprises one or more nucleotide substitutions.

28. The aptamer-interference RNA molecule of claim 27, wherein the nucleotide substitutions comprise at least one or combinations thereof, of adenine, guanine, thymine, cytosine, uracil, purine, xanthine, diaminopurine, 8-oxo-N⁶-methyladenine, 7-deazaxanthine, 7-deazaguanine, N⁴,N⁴-ethanocytosin, N⁶,N⁶-ethano-2,6-diaminopurine, 5-methylcytosine, 5-(C³—

C⁶)-alkynylcytosine, 5-fluorouracil, 5-bromouracil, pseudoisocytosine, 2-hydroxy-5-methyl-4-triazolopyridin, isocytosine, isoguanin, inosine, non-naturally occurring nucleobases, locked nucleic acids (LNA), peptide nucleic acids (PNA), variants, mutants and analogs thereof.

29. The aptamer-interference RNA molecule of claim 22, wherein the aptamer is specific for molecules comprising 4-1BB (CD137), OX40, CD3, CD28, or HLA-DR, CD11c, mannose receptor or DEC205variants, mutants, alleles and fragments thereof.

30. The aptamer-interference RNA molecule of claim 22, wherein the interference RNA (RNAi) is specific for polynucleotides comprising TGFβ

receptor, polynucleotides associated with TGFβ

signaling, purinergic receptors, CTLA-4, PTEN, Csk, Cb1-b, cytokines, SOCS1, GILT, GILZ, A20 or Bax/Bak.

31. The aptamer-interference RNA molecule of claim 22, wherein the aptamer is specific for 4-1BB (CD137), OX40, CD3, CD28, HLA-ABC, HLA-DR, T Cell receptor α

β

(TCRα

β

), T Cell receptor γ

δ

(TCRγ

δ

), T cell receptor ζ

(TCRζ

), TNF receptor, Cd11c, CD1-339, B7, mannose receptor, or DEC205, variants, mutants, ligands, alleles and fragments thereof.

32. The aptamer-interference RNA molecule of claim 22, wherein the interference RNA comprising at least one of a short interfering RNA (siRNA);

a micro, interfering RNA (miRNA);

a small, temporal RNA (stRNA);

or a short, hairpin RNA (shRNA).

33. A composition for modulating immune cells comprising a targeting agent-interference RNA (RNAi) fusion molecule wherein said molecule is targeted to cells and cellular molecules associated with regulation of an immune response, comprising at least one targeting agent which specifically binds to at least one molecule.

34. The composition of claim 33, wherein the interference RNA comprising at least one of a short interfering RNA (siRNA);

a micro, interfering RNA (miRNA);

a small, temporal RNA (stRNA);

or a short, hairpin RNA (shRNA).

35. The composition of claim 33, wherein the immune cells comprise T cells (T lymphocytes), B cells (B lymphocytes), antigen presenting cells, dendritic cells, monocytes, macrophages, myeloid suppressor cells, natural killer (NK) cells, cytotoxic T lymphocytes (CTLs), CTL lines, CTL clones, CTLs from tumor, inflammatory, or other infiltrates and subsets thereof.

36. The composition of claim 33, wherein the targeting agent comprising:

aptamers, antibodies, integrins, receptors, ligands, peptides, or RGD based peptides.

37. The composition of claim 33, wherein the aptamer is specific for T lymphocytes and subsets thereof comprising:

CD8⁺T lymphocytes or markers thereof.

38. The composition of claim 33, wherein the aptamer or targeting agents are specific for T regulatory cells.

39. The composition of claim 33, wherein the aptamer or targeting agents are specific for molecules comprising 4-1BB (CD137), OX40, CD3, CD28, HLA-ABC, HLA-DR, T Cell receptor α

β

(TCRα

β

), T Cell receptor γ

δ

(TCRγ

δ

), T cell receptor ζ

(TCRζ

), TNF receptor, Cd11c, CD1-339, B7, mannose receptor, or DEC205, variants, mutants, ligands, alleles and fragments thereof.

40. The composition of claim 33, wherein the interference RNA (RNAi) is specific for polynucleotides comprising TGFβ

receptor, polynucleotides associated with TGFβ

signaling, purinergic receptors, CTLA-4, PTEN, Csk, Cb1-b, cytokines, SOCS1, GILT, GILZ, A20 or Bax/Bak.

41. The composition of claim 40 wherein the interference RNA (RNAi) is specific for polynucleotides associated with TGFβ

signaling.

42. The composition of claim 33, wherein the RNAi targets TGFβ

in activated T lymphocytes.

43. The composition of claim 33, wherein two or more targeting agents specifically bind to different molecules or same molecules.

44. A method of treating tumors in vivo comprising:

administering to a patient in need thereof a therapeutically effective chimeric molecule which specifically binds to immune cells or cells in tumor vasculatures; and

,

treating tumors in vivo.

45. The method of claim 44, wherein the chimeric molecule comprises one or more targeting agents with same or different specificities fused or linked to an interference RNA molecule.